The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNAbinding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNAbinding activity in human tumors. Heterodimer DNAbinding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Kubinding activity 3 ± 10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5 ± 4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity signi®cantly diered between tumor and normal tissues, displaying a 2 ± 10-fold increase in neoplastic tissues. Three dierent patterns combining both Ku expression and activity with tumor characteristics were identi®ed. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer bindingactivity matched the protein levels. In non-invasive bladder carcinomas no signi®cant dierences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no dierences were demonstrated between normal and tumor protein levels. Our results suggest a dierent modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-speci®c protein expression and post-translational regulation of heterodimer activity. Oncogene (2001) 20, 739 ± 747.
The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNAbinding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNAbinding activity in human tumors. Heterodimer DNAbinding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Kubinding activity 3 ± 10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5 ± 4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity signi®cantly diered between tumor and normal tissues, displaying a 2 ± 10-fold increase in neoplastic tissues. Three dierent patterns combining both Ku expression and activity with tumor characteristics were identi®ed. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer bindingactivity matched the protein levels. In non-invasive bladder carcinomas no signi®cant dierences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no dierences were demonstrated between normal and tumor protein levels. Our results suggest a dierent modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on Introduction Ecient repair of DNA double-strand breaks is crucial for cells to maintain genomic integrity. Unrepaired DNA or inaccurate DNA repair can lead to the generation of cells with tumorigenic potential (Chu, 1997; Berwick and Vineis, 2000) . Previous studies have shown that tumor induction and progression are characterized by accumulation of multiple genetic alterations in the long and complex evolution of cells from normal to malignant phenotype (Fearon and Vogelstein, 1990) . Moreover, increased levels of DNA synthesis in tumor cells are associated with extensive genetic damage. Therefore, the observed high levels of DNA synthesis and genetic mutations in tumors strongly suggest that alterations in DNA repair machinery of these cells may contribute to uncontrolled and error-prone DNA synthesis (Sato et al., 1991; Sekowsky et al., 1998) . Compelling evidences suggest that tumor cells may acquire chemo-and radio-resistance during tumor progression, modulating the activity of the DNA repair machinery (Kessell, 1994; Morgan and Murnane, 1995; Powell and Abraham, 1993; Kinsella et al., 1997) . Furthermore, radiosensitivity in human tumors may arise as a consequence of individual dierences in DNA repair eciency and in the number of initial lesions produced.
Although current histopathological and cytogenetic methods can provide some prognostic information (Dahiya and Deng, 1998; De Vita et al., 1991) , relatively little is known about molecular genetic alterations or dysfunctions of DNA repair machinery, leading to tumor development and progression.
The DNA-dependent protein kinase (DNA-PK) is a serine-threonine protein kinase that requires DNA double-strand ends for its activity (Gottlieb and Jackson, 1993) . It consists of at least two components: a polypeptide of Mr 460,000 containing a kinase catalytic domain (DNA-PKcs) and the Ku protein.
Ku protein is heterodimer of Mr 70,000 and Mr 80,000 subunits that binds with high anity to free doublestranded DNA termini (Mimori and Hardin, 1986) . Additional mutational analysis has shown that Ku activation of DNA-PK well correlates with Ku DNAend binding and hetero-dimerization (Wang et al., 1998) . Once anchored to the DNA, Ku heterodimer translocates along the DNA being the ®rst mediator of DNA repair. Ku associates and dissociates from DNA-PK in vivo as well as in vitro and this process modulates the DNA repair response (Zhang and Yaneva, 1992; . DNA-PK complex is involved in DNA double-strand breaks repair (Chu, 1997) and in several other physiological or pathological events occurring after ionizing radiations exposure , in B and T cell V(D)J recombinations (Jackson and Jeggo, 1995; Bogue and Roth, 1996) , DNA synthesis and transcription .
Ku70/80 and DNA-PK, by virtue of their association with DNA repair and recombination, were supposed to belong to the caretaker class of tumorsuppressor genes that includes ATM, BRCA-1 and BRCA-2 (Kinzler and Vogelstein, 1997; Jhappan et al., 1997) . Ku70 and Ku80 de®ciencies facilitate neoplastic growth, suggesting their role in tumor suppression (Nussenzweig et al., 1997; Li et al., 1998) . It has been demonstrated that Ku80 may act as a caretaker gene that maintains the integrity of the genome by a mechanism involving the suppression of chromosomal rearrangements (Di®lippantonio et al., 2000) . Fresh cells from Ku80 knock-out mice display a marked increase in chromosome aberrations including breakage, translocations and aneuploidy. Loss of p53 synergizes with Ku80 to promote tumorigenesis (Di®lippantonio et al., 2000) . Although dierences were recently demonstrated at the expression level of DNA-PKcs and Ku80 subunits in normal and neoplastic human tissues (Moll et al., 1999) , no data are available on Ku70/80 binding activity and expression in cancerous human tissues.
Therefore, we have evaluated the Ku70/80 DNAbinding activity and characterized its expression in human breast and bladder carcinomas at various stages and grades.
Our results show that there is a great discrepancy in Ku70/80 binding activity between normal and tumor tissues. The tumor tissues examined revealed the existence of two dierent patterns of DNA-binding activity, possibly correlated to the progression of the neoplastic disease. Furthermore, we demonstrate that Ku70 and Ku80 expression is dierentially regulated in the human tissues examined. Data suggest a tissuespeci®c regulation of Ku70/80 protein expression, con®rming previous results about the existence of a post-transcriptional mechanism regulating the protein levels (Moll et al., 1999 ).
Our ®ndings suggest a possible correlation among Ku70/80 DNA-binding activity, genomic instability and tumor progression.
Results

DNA-binding activity in breast and bladder human tumor biopsies
To evaluate the DNA-binding activity of the Ku70/80 heterodimer in tumor biopsies, nuclear and cytoplasmic extracts were prepared from eight breast and seven bladder carcinomas. Breast ductal-or lobular-carcinomas and bladder transitional cell carcinomas (TCCs) were characterized for grading and staging, according to WHO and Tumor-Node-Metastasis classi®cation. Table 1 summarizes the main clinical and histological features. The per cent of mutated p53 obtained by immunohistochemical analysis is evident for the breast cancer samples.
Nuclear and cytoplasmic extracts from the corresponding breast and bladder normal tissues were used as controls. The DNA-binding activity was assayed by EMSA. Proof of the speci®city of the Ku70/80-binding was obtained by addition of goat polyclonal anti-Ku70 and anti-Ku80 antibodies.
In the presence of these antibodies the DNA-end binding complexes were completely supershifted and retarded in the gel (Figure 1f ), indicating that these complexes corresponded to the Ku heterodimer. The DNA-binding activity of all nuclear extracts shown in Figure 1 were normalized for Sp-1 DNA-binding activity.
Nuclear extracts from tumor tissues displayed two dierent patterns of Ku DNA-binding activity ( Figure  1 ). Ten out of 15 tumors showed high Ku binding activity as compared to normal tissues, irrespective of bladder or breast origin. Conversely, a decrease in heterodimer activity was found in 5/15 primary tumors from breast and bladder and in 3/3 metastatic nodes from breast cancers, as compared to the corresponding normal tissues (Figure 1 ). CaCo-2 cell line extracts were used as standard in order to compare the activity in the dierent gels. Two-tailed Student's t-test was carried out to evaluate the statistical signi®cance of dierence between normal vs tumor samples.
In ®ve breast and ®ve bladder tumors the DNAbinding activity was 3 ± 10 times higher (Figure 1 : patients A ± E and patients I ± M) as compared to normal tissues (P50.00004). All breast tumors of this group were classi®ed at T1, G1 ± G2, according to WHO and TNM classi®cation (Table 1) , and displayed a less aggressive clinical phenotype. Bladder tumors were non-invasive or in®ltrating the submucosa (Ta ± T1, G1 ± G2) ( Table 1 ). All normal tissues displayed a very low basal level of DNA-binding activity.
The second group of tumors, characterized by a decreased Ku binding activity, was associated with a more advanced progression according to tumor staging and/or grading. Three aggressive synchronous bilateral breast tumors (G3 ± G2, T2) (Table 1: F, G 1 and G 2 ) and two urothelial carcinomas highly in®ltrating the bladder wall (G3,T3), (Table 1 : N,O) showed a 1.5 ± 3-fold decrease in DNA-binding activity as compared to their normal counterparts (P50.001) (Figure 1 , patients F, G 1 , G 2 , N, O). A similar pattern of Ku activity was obtained from lymph nodes of patients A, B and G. In the metastatic axillary nodes of these patients the DNA-binding activity was down-modulated (2.5 ± 4.5 times), as compared to the corresponding primary tumors and to a histopathologically normal node (metastases vs primary tumors: P50.0002) (Figure 1e ).
Ku DNA-binding activity was also analysed in a bladder tissue with histological diagnosis of chronic in¯ammation, from a cancer-free patient ( Figure 1 , patient Q). DNA-binding activity was completely absent both in pathologic and in normal tissues.
Tumors with a less aggressive behavior displayed a high DNA-binding activity in the nuclei, when compared to the normal tissues. Moreover, both advanced and metastatic tumors showed a substantial decrease in Ku70/80 DNA-binding activity.
These results highlight a signi®cant divergence of Ku DNA-binding activity in less aggressive or invasive and metastatic tumors and their normal counterparts.
Ku70/80 DNA-binding activity in normal and tumor cytoplasmic extracts
To assess whether the DNA-binding activity was present in other cellular compartments we assayed the cytoplasmic extracts of the same patients. The results are shown in Figure 2 . In almost all normal tissues Ku70/80 DNA-binding activity was barely detectable whereas the cytoplasmic extracts from breast and bladder tumors displayed a high DNA-binding activity. Figure 2 shows a 2 ± 10-fold increase in the Ku70/80 activity in seven breast and four bladder cancers (Figure 2 , patients A ± F, G 2 , I,J,L,M), as compared to the corresponding controls. All tumor cytoplasmic extracts displayed a similar level of DNA-binding activity. The highest activity of the heterodimer was found in the cytoplasmic extract from a bilateral breast cancer (Figure 2 , patient F). A very low activity, as in the other normal tissues, was present in the cancer-free patient (Figure 2 , patient Q). To verify the absence of nuclear protein contamination, Sp-1 DNA-binding activity was assayed in the cytoplasmic extracts from normal and tumor breast tissues (Figure 2c ).
p70 and p80 protein expression in normal and tumor tissues
To determine whether the dierent DNA-binding activity in normal and tumor tissue was due to a dierent production of the p70 and p80 proteins or to a modulation of the heterodimer activity, nuclear levels of Ku70 and Ku80 proteins were examined by Western blot analysis in the same extracts. The expression of the two subunits (densitometrically determined) was always in the ratio 1 : 2 (p80 : p70) both in normal and tumor tissues, suggesting the possibility that p80 may be the limiting factor for heterodimer formation. Figure 3 shows the nuclear p70 and p80 expression in tumors and in the corresponding normal tissues (Figure 3b,c) . Representative Western blot shows the dierences between normal and tumor nuclear extracts from breast samples, in p70 protein levels. Sp-1 nuclear levels are shown as reference controls (Figure 3a) . Protein expression was also analysed in three metastatic nodes and one normal node (Figure 3d) .
In ®ve breast tumors (Figure 3 , samples A ± E), p70 and p80 proteins were expressed in tumor extracts but they were absent or expressed at very low level in normal tissues. A 4 ± 18-fold increase of protein expression was present in tumor extracts, as compared to the normal tissues (Figure 3b , samples A ± E). On the contrary, no signi®cant dierences in protein expression between tumors and their normal counterparts were found in any bladder sample analysed (Figure 3b , samples I ± M).
In nuclear extracts from three bilateral breast samples (F, G 1 , G 2 ) and from two highly invasive TCC (N, O), the two subunits were present at the same level in both normal and tumor tissues Figure 3) . The protein levels did not correlate with the heterodimer binding-activity. The metastatic tissues displayed a similar behavior; in fact p70 and p80 were both present in metastatic nodes, in primary tumor tissues and in one normal node (Figure 3d , samples A, B and G 2 ), without any correlation with the corresponding Ku70/80-activity.
Correlation among DNA-binding activity, protein levels and tumor stage Three dierent patterns combining both Ku expression and activity with tumor characteristics were identi®ed (Table 2 ).
In the ®rst group including the less aggressive breast cancer samples, Ku70 and Ku80 expression levels matched with the concomitant increase of nuclear DNA-binding activity (Figures 1 and 3, patients A ± D) .
No correlation between the protein levels and the corresponding binding activity was found in noninvasive transitional cell carcinomas, forming the second group. In these samples, the heterodimer binding activity was up-regulated in all nuclear tumor extracts, although there were no dierences in the protein levels between tumor and normal tissues (Figures 1 and 3 , samples I ± M). A third group, composed by bilateral synchronous breast tumors, the highly in®ltrating bladder cancers and the metastatic node tissues, showed no correlation between the protein levels and the binding activity, which decreased in all tumor and metastatic node extracts, although p70 and p80 levels did not show signi®cant dierences between normal and tumor tissues (Figures 1 and 3, samples F, G 1 , G 2 , N, O) .
Discussion
Mammary and urothelial tumors are two of the most frequent cancers in Western countries. They show a strong correlation between high rates of DNA synthesis and poor overall patient prognosis (Wong et al., 1999; O'Neill et al., 1992; Korkolopoulou et al., 1997; Cordon-Cardo, 1998) . Several observations correlate Ku70/80 heterodimer function, DNA repair and tumor development (Di®lippantonio et al., 2000) , but no direct evidences of Ku70/80 activity in human tumor tissues have been published up to date. Recent reports suggest that Ku70/80 DNA-binding activity could indicate the cellular capacity to maintain genomic integrity and could be used as a marker of the DNA repair capability (Hwang et al., 1999) .
In the present study we have investigated the Ku70/ 80 DNA-binding activity in human breast and bladder normal and tumor biopsies. The tumor tissues examined revealed the existence of two dierent patterns in DNA-binding activity, overall correlated to the progression of the neoplastic disease. T1, G1 ± G2 breast-and non-invasive bladder tumors (Ta, T1) showed a high nuclear DNA-binding activity. Conversely, all the corresponding normal tissues displayed a very low basal level of the DNAbinding activity.
These data could suggest that an increased and uncontrolled proliferation, at the onset of cancer, determines an activation of the DNA repair system, in attempt to reduce the high rate of mistakes that could lead to an increased genomic instability. This hypothesis is consistent with the data found in the two non-invasive TCCs at the early stage of disease (Ta), where the DNA-binding activity was strongly upregulated. Figure 3 p70 and p80 nuclear expression from breast, bladder and metastatic node tissues. (a) Western blot analysis by using antiKu70 or anti-Sp-1 antibody in the normal (n) and tumoral (t) nuclear extracts of breast tissue (patients A ± D, F, G 1 , G 2 ) (b,c,d) Histograms represent the scanning densitometric analysis of Western blots performed as described in Materials and methods. Each value was normalized for Sp-1 protein levels and represent the mean (+s.d.) of three independent experiments. (b) Expression levels of nuclear p70 and p80 subunits, in breast normal (n) and tumoral (t) nuclear extracts. Capital letters on x axis indicate the patients (Table 1) . (c) p70 and p80 levels from nuclear extracts of bladder tissues;`n',`t' and`p' label normal, tumoral and peritumoral tissues, respectively. (d) p70 and p80 levels from nuclear extracts of breast primary tumors (t) and metastatic nodes (m) of patients A, B and G. One normal node (n) of patient A is also analysed c (+) symbols indicate the 3 ± 10-fold increase of activity (or 4 ± 18-fold increase of protein expression). (7) mark the decrease of 1.5 ± 4.5 times in DNA-binding activity The decreased nuclear DNA-binding activity found in the advanced and metastatic tumors could be due to a mechanism that inhibits cellular repair of spontaneous DNA-damage, by inactivating the DNA-repair activity of the heterodimer. This inhibition could determine an increased tumor progression. In fact cell malignancy progression is accompanied by accumulation of multiple genetic mutations, created by errorprone DNA replication and reduction of DNA-repair eciency (Loeb and Loeb, 2000) .
In these aggressive tumors no correlation was found between protein levels and DNA-binding activity. In fact there are no evident dierences at the protein level both in normal and in tumoral tissues. This data suggests the existence of an inhibitory mechanism that regulates the Ku70/80-activity. It has been demonstrated that speci®c RNAs (Yoo and Dynan 1998) and Ku-binding proteins, KUBS (Yang et al., 1999) are capable to bind a subunit of the heterodimer reducing the DNA repair activity by steric inhibition. A similar mechanism of inhibition of the DNA-binding capability could act in the aggressive tumors and in the metastatic node tissues analysed. It has been recently demonstrated that a KUB protein CLU/XIP-8, complexed to Ku70/Ku80, may constitute a signal for killing severely damaged cells (Yang et al., 2000) . The p53 altered status may interfere with the apoptotic signal mediated by CLU/XIP-8-Ku70/Ku80 complexes. The high percentage of mutated p53 and the downregulated Ku DNA-binding activity found in bilateral breast cancers seem to be in agreement with the more aggressive behavior of these tumors.
The existence of the heterodimer in the cytoplasm and its potential DNA-binding activity was assayed. High DNA-binding activity was found in the cytoplasmic extracts of all tumor tissues, con®rming the presence of the Ku70/80 heterodimer in the cytoplasm and its functional capacity to bind DNA-ends. The biological signi®cance of this issue is still unknown although it seems probable that the heterodimer would be able to migrate between the cellular compartments as a result of intriguing interactions of proliferative and antiproliferative signals (Bandyopadhyay et al., 1998; Koike et al., 1999; Tovari et al., 1998) . The presence of the single subunits of the hetherodimer has also recently been demonstrated in the cytoplasmic membrane (Prabhakar et al., 1990; Dalziel et al., 1992) . It seems that Ku70 and Ku80 may also behave as cellular receptors, interacting with growth factors and their antagonists (Le Romancer et al., 1994; Teoh et al., 1998) .
Among the examined human tissues the two components of DNA-PK appeared to be dierentially expressed. No protein or low protein expression levels were observed in normal tissues from the mammary gland, con®rming the immunohistochemical data published in a previous report (Moll et al., 1999) . On the contrary, p70 and p80 were detected in normal urothelial tissues. This evidence suggests that Ku70/80 expression could be regulated in a tissue-speci®c manner.
In conclusion, our study demonstrates, for the ®rst time, the dierent Ku70/80 DNA-binding activities in normal and tumor breast and bladder tissues and the dierent expression levels of the single subunits, in the same samples. Moreover, results show the downregulation of the heterodimer DNA-repair capability in highly aggressive and metastatic breast and bladder human tumors.
Extensive epidemiological studies are still necessary to clarify the correlation between DNA-binding activity and tumor progression and the role of Ku70/ 80, as a predictive or prognostic marker.
Materials and methods
Patients characteristics and tissue samples
Seven patients with breast cancer who underwent radical mastectomy or tumor excision and seven patients with bladder cancer who underwent transurethral resection (TUR-B) or radical cystectomy, were recruited in the study. One patient, suspected of bladder cancer (Table 1 , patient Q), had no histopathological evidence of malignant transformation. Two patients (Table 1 , patients F and G) had bilateral breast cancer, at clinical onset. Normal breast or bladder tissues were collected from each patient and they were used as controls. From one bladder cancer patient (Table 1, J) peritumoral tissues was also collected, immediately next to the lesion.
Three histologically metastatic nodes obtained from three breast cancer patients (samples A, B and G 2 ) and one normal node (sample A) were also included in the study.
All specimens used in this study underwent histological examination to con®rm the diagnosis. None of the patients had received any therapy before surgery.
Preparation of cell and nuclear extracts
Following surgical resection, tissue samples were immediately processed for protein extraction. Post-nuclear and nuclear extractions were performed according to Dignam et al. (1983) . Tissue samples were put on ice and mechanically fractionated to obtain a cellular suspension. Afterwards, red blood cells were depleted by osmotic lysis. Cells were then washed twice and suspended in 0.5 ml of ice-cold buer A (HEPES-KOH 10 mM, pH 7.9, MgCl 2 1.5 mM, KCl 10 mM, EDTA 1 mM and DTT 1 mM, PMSF 1 mM, NaF 20 mM, Na 4 P 2 O 7 1 mM added just prior to use); cells were allowed to swell on ice for 20 min; then 25 ml of Nonidet P-40 10% (Fluka-SIGMA, St Louis, MO, USA) was added. The homogenate was centrifuged for 30 s in a microfuge at 10 000 r.p.m.; the post-nuclear extract containing cytoplasmic proteins was carefully removed from the nuclear pellet and stored at 7808C.
The nuclear pellet was resuspended in ice-cold NaClextraction buer (HEPES-KOH 20 mM pH 7.9, NaCl 420 mM, MgCl 2 1.5 mM, EDTA 1 mM, glycerol 25% and DTT 1 mM, PMSF 1 mM, NaF 20 mM, Na 4 P 2 O 7 1 mM, added just prior to use) and incubated on ice for 30 min. Cellular debris were removed by centrifugation for 5' in a microfuge at 10 000 r.p.m. The supernatant fraction, containing DNA binding proteins, was stored at 7808C. All steps of protein extraction were checked by optical microscope.
Protein content in the cytoplasmic and nuclear extracts was determined in triplicate by Bradford assay (Bio-Rad Protein Assay, Bio-Rad Laboratories-Munchen).
DNA end binding (mobility-shift gel electrophoresis assay)
The electrophoretic mobility shift assay (EMSA) was performed as described previously (Zhang and Yaneva, 1992) . A 32 P-end labeled 56 bp DNA probe (Frasca et al., 1998) was incubated with nuclear or cytoplasmic extracts for 30' at room temperature in binding buer (10 mM Tris-HCl pH 8, EDTA 0.5 mM, NaCl 150 mM, DTT 1 mM, PMSF 1 mM, glycerol 10%); brie¯y, the DNA binding reactions contained: the labeled probe (50 000 c.p.m.), nuclear (2 mg) or cytoplasmic (5 mg) extracts and closed circular plasmid DNA pUC-19 (0.7 mg ± 1 mg), as unspeci®c competitor.
To normalize all nuclear samples, EMSA was performed incubating the nuclear extracts (3 mg) with 50 000 c.p.m./ sample of 32 P-end labeled Sp-1 Oligonucleotide (Promega Corporation, Madison WI, USA) in binding buer (glycerol 20%, MgCl 2 5 mM, EDTA 2.5 mM, NaCl 250 mM, Tris-HCl pH 7.5 50 mM, DTT 2.5 mM) with 1 mg of poly(dI-dC) as unspeci®c competitor. For gel supershift experiments goat polyclonal anti-Ku70 and anti-Ku80 antibodies (Santa-Cruz Biotechnologies Inc.) were incubated with protein extracts for 30' at room temperature, before adding the other components to the reaction.
Complexes were separated on 6% nondenaturing polyacrylamide gels, in TBE (45 mM Tris-borate, 1 mM EDTA, pH 8.0) at 200 V for 2 h, 30 min. Gels were dried and exposed to X-ray ®lms (Amersham ± LifeScience), overnight at 7808C. The optical densities were obtained by scanning densitometry, using colon carcinoma cell line extracts (CaCo-2, ATCC) as internal control.
Western blotting
Protein extracts (10 mg) were boiled in SDS ± PAGE loading buer and separated by 10% SDS ± PAGE. Proteins were transferred to a PVDF membrane (Hybond-P, Amersham ± LifeScience) using an electroblotting apparatus and incubated for 1 h at RT with 1% BSA, 1% skim milk (Difco Lab. Detroit, MI, USA) and 0.5% Tween 20 (USB, Cleveland, Ohio, USA). Membranes were stained with Poinceau S dye, to check for equal loading and homogenous transfer.
Primary antibodies (goat polyclonal IgG anti-Ku70 or Ku80, Santa Cruz Biotechnologies, Inc) were diluted 1 : 500 in 1% BSA and incubated for 1 h at room temperature; samples were washed extensively with 0.5% Tween-20 and diluted 1 : 8000 secondary antibody (anti-goat-HRP IgG, Santa Cruz Biotechnologies, Inc) was added in 1% BSA, 1% milk, 0.5% Tween-20, for 1 h at room temperaure. Filters were reprobed with anti b-actin (Sigma-Aldrich, Saint Louis, Missouri 63103-USA) or anti-Sp-1 (Santa Cruz Biotechnologies, Inc.) mouse IgG 1 monoclonal antibodies, to normalize respectively cytoplasmic or nuclear protein levels.
Filters were washed and developed using an enhanced chemiluminescence system (ECL, Amersham-Pharmacia Biotech).
